The FDA may require the manufacture of a drug to post a prominent "black box" warning when:
a. The drug receives IND status (Investigational new drug)
b. Following phase one human testing
c. Unlabeled uses of the drug occur
d. A problem may arise that may lead to death or severe injury if the medication is used
d
Rationale: a. A drug gains the status of investigational new drug when it has completed its preclinical testing phase and is ready for human testing.
b. The primary purpose of phase one testing is to determine the pharmacokinetics, toxicity, and safe dose in humans.
c. Unlabeled uses of a drug may occur when a physician or group of peers determines that a drug that has indications for one disorder inadvertently is beneficial for another disorder that it was not given an indication for during the human testing phases.
d. The FDA requires a prominent "black box" warning when the use of a prescribed drug may lead to death or injury as a result of its use.
You might also like to view...
In most people, the inferior aspect of the left ventricle receives its blood supply from the:
A) circumflex artery. B) right coronary artery. C) left main coronary artery. D) left anterior descending artery.
Environmental control units (ECUs) ______________________________________.?
A) allow a person with a disability to navigate unfamiliar environments B) ?allow a person who has limited mobility to perform many everyday functions in the home, at work, or school C) are physical locations within rehabilitation hospitals in which the environment is carefully controlled for treatment purposes D) ?are air-conditioning and heating units that also include air purification systems for individuals with compromised respiratory function